scholarly journals Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer

2005 ◽  
Vol 41 (17) ◽  
pp. 2637-2644 ◽  
Author(s):  
A.C. Voogd ◽  
F.J. van Oost ◽  
E.J.T. Rutgers ◽  
P.H.M. Elkhuizen ◽  
A.N. van Geel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Local Recurrence ◽  
Early Breast Cancer ◽  
Conservative Surgery ◽  
Long Term Prognosis

scholarly journals Detection of local recurrence following breast-conserving treatment in young women with early breast cancer: Optimization of long-term follow-up strategies

The Breast ◽  
2013 ◽  
Vol 22 (3) ◽  
pp. 351-356 ◽  
Author(s):  
Maurice J.C. van der Sangen ◽  
Sanne W.M. Scheepers ◽  
Philip M.P. Poortmans ◽  
Ernest J.T. Luiten ◽  
Grard A.P. Nieuwenhuijzen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Local Recurrence ◽  
Early Breast Cancer ◽  
Young Women ◽  
Breast Conserving Treatment ◽  
Long Term Follow Up

Conservative surgery, external radiotherapy, and HDR brachytherapy in a single fraction of 7 Gy in early breast cancer: long-term toxicity and esthetic assessment

2012 ◽  
Vol 14 (12) ◽  
pp. 953-960 ◽  
Author(s):  
Aurora Rodríguez Pérez ◽  
Maria Concepción López Carrizosa ◽  
Pilar Maria Samper Ots ◽  
José Fermín Pérez-Regadera Gómez ◽  
José Zapatero Ortuño ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Conservative Surgery ◽  
Hdr Brachytherapy ◽  
External Radiotherapy ◽  
Single Fraction

scholarly journals Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial

BMJ ◽  
2020 ◽  
pp. m2836 ◽  
Author(s):  
Jayant S Vaidya ◽  
Max Bulsara ◽  
Michael Baum ◽  
Frederik Wenz ◽  
Samuele Massarut ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Single Dose ◽  
Local Recurrence ◽  
Early Breast Cancer ◽  
External Beam Radiotherapy ◽  
Breast Cancer Mortality ◽  
Intraoperative Radiotherapy ◽  
Term Survival ◽  
Free Survival

AbstractObjectiveTo determine whether risk adapted intraoperative radiotherapy, delivered as a single dose during lumpectomy, can effectively replace postoperative whole breast external beam radiotherapy for early breast cancer.DesignProspective, open label, randomised controlled clinical trial.Setting32 centres in 10 countries in the United Kingdom, Europe, Australia, the United States, and Canada.Participants2298 women aged 45 years and older with invasive ductal carcinoma up to 3.5 cm in size, cN0-N1, eligible for breast conservation and randomised before lumpectomy (1:1 ratio, blocks stratified by centre) to either risk adapted targeted intraoperative radiotherapy (TARGIT-IORT) or external beam radiotherapy (EBRT).InterventionsRandom allocation was to the EBRT arm, which consisted of a standard daily fractionated course (three to six weeks) of whole breast radiotherapy, or the TARGIT-IORT arm. TARGIT-IORT was given immediately after lumpectomy under the same anaesthetic and was the only radiotherapy for most patients (around 80%). TARGIT-IORT was supplemented by EBRT when postoperative histopathology found unsuspected higher risk factors (around 20% of patients).Main outcome measuresNon-inferiority with a margin of 2.5% for the absolute difference between the five year local recurrence rates of the two arms, and long term survival outcomes.ResultsBetween 24 March 2000 and 25 June 2012, 1140 patients were randomised to TARGIT-IORT and 1158 to EBRT. TARGIT-IORT was non-inferior to EBRT: the local recurrence risk at five year complete follow-up was 2.11% for TARGIT-IORT compared with 0.95% for EBRT (difference 1.16%, 90% confidence interval 0.32 to 1.99). In the first five years, 13 additional local recurrences were reported (24/1140 v 11/1158) but 14 fewer deaths (42/1140 v 56/1158) for TARGIT-IORT compared with EBRT. With long term follow-up (median 8.6 years, maximum 18.90 years, interquartile range 7.0-10.6) no statistically significant difference was found for local recurrence-free survival (hazard ratio 1.13, 95% confidence interval 0.91 to 1.41, P=0.28), mastectomy-free survival (0.96, 0.78 to 1.19, P=0.74), distant disease-free survival (0.88, 0.69 to 1.12, P=0.30), overall survival (0.82, 0.63 to 1.05, P=0.13), and breast cancer mortality (1.12, 0.78 to 1.60, P=0.54). Mortality from other causes was significantly lower (0.59, 0.40 to 0.86, P=0.005).ConclusionFor patients with early breast cancer who met our trial selection criteria, risk adapted immediate single dose TARGIT-IORT during lumpectomy was an effective alternative to EBRT, with comparable long term efficacy for cancer control and lower non-breast cancer mortality. TARGIT-IORT should be discussed with eligible patients when breast conserving surgery is planned.Trial registrationISRCTN34086741, NCT00983684.

scholarly journals Long-term results of hypofractionation with concomitant boost in patients with early breast cancer: A prospective study

PLoS ONE ◽  
2021 ◽  
Vol 16 (10) ◽  
pp. e0258186
Author(s):  
Kitwadee Saksornchai ◽  
Thitiporn Jaruthien ◽  
Chonnipa Nantavithya ◽  
Kanjana Shotelersuk ◽  
Prayuth Rojpornpradit
Keyword(s):  
Breast Cancer ◽  
Local Recurrence ◽  
Early Breast Cancer ◽  
Long Term Results ◽  
Whole Breast Irradiation ◽  
Breast Irradiation ◽  
Sequential Boost ◽  
Concomitant Boost ◽  
Hypofractionated Whole Breast Irradiation

Aim To report the long-term local control and survival of patients with early breast cancer who had hypofractionated whole breast irradiation with concomitant boost (Hypo-CB). Methods and materials Between October 2009 and June 2010, 73 patients with early breast cancer (T1-3N0-1M0) who underwent breast conserving surgery were enrolled into the study. Thirty-six of these participants received 50 Gy of conventional irradiation in 25 fractions over 5 weeks to the whole breast with a sequential boost to the tumor bed with 10–16 Gy in 5–8 fractions (Conv-SEQ). The other 37 participants received a hypofractionated dose of 43.2 Gy in 16 fractions with an additional daily concomitant boost (CB) of 0.6 Gy over 3 weeks (Hypo-CB). Results At a median follow-up time of 123 months, ipsilateral local recurrence (ILR) was found in 3 participants, 1 of whom was in the hypofractionated group. All 3 ILR were true local recurrence (TR). There were no significant differences in the 10-year disease free survival (DFS) and 10-year overall survival rates (OS) between the conventional and hypofractionated groups (93.9% vs. 94.4%, p = 0.96 and 91.9% vs. 91.6%, p = 0.792, respectively). Conclusion This study showed that the effectiveness, DFS and OS were comparable between hypofractionated whole breast irradiation with a CB and the conventional irradiation with a sequential boost.

Sign in / Sign up

Export Citation Format

Share Document